Association between Interlukin-6 (IL-6), Interlukin-10 (IL-10) and depression in patients undergoing Hematopoietic stem cell transplantation.
AbstractThe release of pro-inflammatory cytokines is responsible for the variety of behavioral, neuro-endocrine and neuro-chemical alterations in psychiatric condition. In this study we evaluate relation between depression and IL-6 and IL-10 in patients undergoing hematopoietic stem cell transplantation (HSCT).66 patients in this cross-sectional study from July 2013 until August 2014 for HSCT interred the study and were assessed for depression using Hospital Anxiety and Depression Scale (HADS). Serum interleukin (IL)-6, (IL)-10 and high sensitive C-reactive protein (hs-CRP) were assessed on the same time. Association between these biomarkers with depression was evaluated using SPSS version 20.A total of 66 patients with the mean age of 41.18+13.92 and 41.95+12.35 years old in non depressed and depressed group respectively were enrolled in this study. Patients with depression showed significantly higher levels of serum IL-6 and the IL-6-to-IL-10 ratio compared to patients without depression (p<0.001).There was no statistically significant association between IL-10 and hs-CRP with depression in this group of the patients.High IL-6 level has significant association with depression in patients undergoing HSCT. In conclusion, since IL-6 can affect the outcomes after HSCT and depression was associated with increased serum IL-6 level, early identification of depression can be beneficial in these patients.
Rocha V, Wagner Jr JE, Sobocinski KA, et al. Graft-versus-host disease in children who h1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med; 2006. 354: 1813–1826.
Ustun TB, Sartorius N. Mental Illness in General Healthcare: An International Study. London: John Wiley &Sons;1995.p.2264.
Farber DM, Wienerman BH, Kuypers JA. Psychosocial distress in oncology outpatients. J Psychosocial Oncol; 1984.2:109–118.
Trask PC, Paterson AG, Hayasaka S, et al. Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol; 2001. 19: 2844–2850.
Stefanek ME, Derogatis LP, Shaw A. Psychological distress among oncology outpatients. Psychosomatics; 1987.28:530–539.
Lee SJ, Loberiza FR, Rizzo JD, et al. Optimistic expectations and survival after hematopoieticnstem cell transplantation. Biol Blood Marrow Transplan;t 2003.9: 389–396.
Loberiza Jr FR, Rizzo JD, Bredeson CN, et al. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol; 2002.20:2118–2126.
Kiecolt-Glaser JK, Glaser R. central pathways to morbidity and mortality. J Psychosom Res; 2002.53: 873 876.
Braamse AM, Gerrits MM, van Meijel B, et al. Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies. Bone Marrow Transplant; 2012.47:757-69.
McGregor BA, Syrjala KL, Dolan ED, et al .The effect of pre-transplant distress on immune reconstitution among adult autologous hematopoietic cell transplantation patients. Brain Behav Immun;2012. 30: S142–S148.
Costanzo ES, Juckett MB, Coe CL. Biobehavioral influences on recovery following hematopoietic stem cell transplantation. Brain Behav Immun;2012. 30: S68–S74.
Knight JM, Lyness JM, Sahler OJZ, et al. Psychosocial factors and hematopoietic stem cell transplantation: Potential biobehavioral pathways. Psychoneuro endocrinology; 2013.38: 2383–2393.
Hoodin F, Uberti JP, Lynch TJ, et al. Do negative or positive emotions differentially impact mortality after adult stem cell transplant? Bone Marrow Transplant; 2006.38,255–264.
Moylan S, Maes M, Wray NR, et al. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry;2013.18,595–606.
Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry; 2010.1:446-57.
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med; 2009.71:171-86.
Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord;2012. 139:230-9.
Mesquita AR, Correia-Neves M, Roque S, et al. IL-10 modulates depressive-like behavior. J Psychiatr Res; 2008.43:89–97.
Roque S, Correia-Neves M, Mesquita AR, et al. Interleukin-10: a key cytokine in depression? Cardiovasc. Psychiatry Neurol; 2009.2009:1–5.
Schots R, Kaufman L, Van Riet I, et al. Monitoring of Creactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant; 1998. 22:79–85.
Cavet J, Dickinson AM, Norden J, et al. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood; 2001.98:1594–600.
Symington FW, Symington BE, Liu PY, et al. The relationship of serum IL-6 levels to acute graft versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation; 1992.54:457–62.
Tegg EM, Griffiths AE, Lowenthal RM, et al Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation. Bone Marrow Transplant; 2001.28(10):929-33.
Holler E, Roncarolo MG, Hintermeier-Knabe R et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant; 2000. 25: 237–241.
Montazeri A, Vahdaninia M, Ebrahimi M, et al.The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version. Health Qual Life Outcomes; 2003. 28;1:14.
Syrjala KL, Chapko MK, Vitaliano PP, et al. Recovery after allogeneic marrow transplanation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant; 1993. 11:319–327.
Andrykowski MA, Bruehl S, Brady MJ, et al. Physical and psychosocial status of adults one-year after bone marrow transplantation: a prospective study. Bone Marrow Transplant; 1995. 15: 837–844.
McQuellon RP, Russell GB, Rambo TD, et al. Quality of life and psychological distress of bone marrow transplant recipients: the ‘time trajectory’ to recovery over the first year. Bone Marrow Transplant; 1998. 21: 477–486.
Maheri Azar R, Nikoogoftar M, Salehi S, et al. Anxiety and Depression in pre-and-post-Hematopoietic Stem Cell Transplants in SCT Center, Shariati Hospital, Tehran, Iran. Int J Hematol Oncol Stem Cell Res; 2010. 4:17-21.
Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol; 2006. 27; 24-31
Alesci S, Martinez PE, Kelkar S, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab;2005.90:2522–2530.
Vogelzang N, Duivis HE, Beekman AT, et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry; 2012.2:e79.
Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuro psycho pharmacology;2011.36:2452-9.
Imamura M, Hashino S, Kobayashi H, et al. Serum cytokine levels in bone marrow transplantation:IJHOSCR, 1 April 2015. Volume 9, Number 2 IL-6, IL-10 and depression in Hematopoietic stem cell transplantation 87 International Journal of Hematology Oncology and Stem Cell Research ijhoscr.tums.ac.ir synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factoralpha in graft-versus-host disease. Bone Marrow Transplant; 1994.13: 745–751.
Testa U, Martucci R, Rutella S, et al. Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood; 1994. 84: 3532–3539.
Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord; 2013. http://dx.doi.org/ 10.1016/j.jad.2013.06.004.
Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med; 2004.10:1010-4.
Ma Y, Chiriboga DE, Pagoto SL, et al. Association between Depression and C-Reactive Protein. Cardiol Res Pract;2010.2011:286509.
Dhabhar FS, Burke HM, Epel ES, et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res; 2009. 43(11): 962-9.
Simon NM, McNamara K, Chow CW, et al. A detailed examination of cytokine abnormalities in Major Depressive Disorder. European Neuro psychopharmacology; 2008.18: 230–3.
Huang TL, Lee CT. T-helper 1/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression. Psychiatry and Clinical Neurosciences; 2007.61:415–20.
O’Brien SM, Scully P, Fitzgerald P, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res; 2007.41:326–31.
Fang Y, Sharp GC, Braley-Mullen H. Interleukin-10 promotes resolution of granulomatous experimental autoimmune thyroiditis. Am J Pathol; 2008.172:1591–602.
Ogawa Y, Duru EA, Ameredes BT. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med; 2008.8:437–45.
Taraz M, Khatami MR, Gharekhani A, et al. Relationship between a pro- and anti-inflammatory cytokine imbalance and depression in haemodialysis patients. Eur Cytokine Netw; 2012.23:179-86.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.